Royal London Asset Management LTD Gilead Sciences, Inc. Transaction History

Royal London Asset Management LTD

$39.3 Billion
Q1 2024

A detailed history of Royal London Asset Management LTD transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Royal London Asset Management LTD holds 1,222,234 shares of GILD stock, worth $83.6 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

1,222,234

Previous 1,044,875 16.97%

Holding current value

$83.6 Million

Previous $84.6 Million 5.77%

% of portfolio

0.23%

Previous 0.25%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $12.7 Million - $15.5 Million	177,359 Added 16.97%	1,222,234 $89.5 Million
Q4 2023 Feb 13, 2024	BUY	$73.27 - $83.09 $14.8 Million - $16.7 Million	201,545 Added 23.9%	1,044,875 $84.6 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $16.5 Million - $18 Million	223,694 Added 36.1%	843,330 $63.2 Million
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $3.06 Million - $3.49 Million	40,233 Added 6.94%	619,636 $47.8 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $3.97 Million - $4.52 Million	-51,328 Reduced 8.14%	579,403 $48.1 Million

Q4 2022 Feb 09, 2023	BUY	$62.32 - $89.47 $563,996 - $809,703	9,050 Added 1.46%	630,731 $54.1 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $1.92 Million - $2.19 Million	-32,231 Reduced 4.93%	621,681 $38.4 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $81,096 - $91,339	-1,405 Reduced 0.21%	653,912 $40.4 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $1.45 Million - $1.82 Million	25,011 Added 3.97%	655,317 $39 Million
Q4 2021 Oct 18, 2022	SELL	$64.88 - $73.64 $1.75 Million - $1.99 Million	-27,025 Reduced 4.11%	630,306 $45.8 Million
Q4 2021 Jan 18, 2022	SELL	$64.88 - $73.64 $1.75 Million - $1.99 Million	-27,025 Reduced 4.11%	630,306 $45.8 Million
Q3 2021 Oct 18, 2022	SELL	$67.69 - $73.03 $1.17 Million - $1.27 Million	-17,327 Reduced 2.57%	657,331 $45.9 Million
Q3 2021 Nov 02, 2021	SELL	$67.69 - $73.03 $1.17 Million - $1.27 Million	-17,327 Reduced 2.57%	657,331 $45.9 Million
Q2 2021 Oct 18, 2022	BUY	$63.47 - $69.35 $1.32 Million - $1.44 Million	20,746 Added 3.17%	674,658 $46.4 Million
Q2 2021 Jul 14, 2021	SELL	$63.47 - $69.35 $1.11 Million - $1.21 Million	-17,429 Reduced 2.52%	674,658 $46.6 Million
Q1 2021 Oct 17, 2022	BUY	$60.0 - $68.46 $2.29 Million - $2.61 Million	38,175 Added 5.84%	692,087 $44.7 Million
Q1 2021 Apr 13, 2021	BUY	$60.0 - $68.46 $1.29 Million - $1.47 Million	21,515 Added 3.21%	692,087 $44.7 Million
Q4 2020 Jan 29, 2021	BUY	$56.65 - $64.55 $40,844 - $46,540	721 Added 0.11%	670,572 $39.1 Million
Q3 2020 Nov 04, 2020	SELL	$62.1 - $78.08 $112,959 - $142,027	-1,819 Reduced 0.27%	669,851 $41.6 Million
Q2 2020 Jul 31, 2020	SELL	$72.34 - $84.0 $1.33 Million - $1.54 Million	-18,363 Reduced 2.66%	671,670 $50.1 Million
Q1 2020 May 01, 2020	BUY	$62.63 - $80.22 $214,006 - $274,111	3,417 Added 0.5%	690,033 $52.4 Million
Q4 2019 Feb 05, 2020	BUY	$61.62 - $67.78 $1.31 Million - $1.44 Million	21,284 Added 3.2%	686,616 $44.6 Million
Q3 2019 Nov 12, 2019	BUY	$62.51 - $69.0 $138,209 - $152,559	2,211 Added 0.33%	665,332 $42.2 Million
Q2 2019 Jul 31, 2019	SELL	$61.87 - $69.38 $1.29 Million - $1.45 Million	-20,914 Reduced 3.06%	663,121 $44.8 Million
Q1 2019 Apr 30, 2019	BUY	$62.53 - $70.05 $833,212 - $933,416	13,325 Added 1.99%	684,035 $0
Q4 2018 Jan 29, 2019	BUY	$60.54 - $79.0 $7.91 Million - $10.3 Million	130,585 Added 24.18%	670,710 $41.5 Million
Q3 2018 Nov 08, 2018	SELL	$71.28 - $78.92 $878,383 - $972,531	-12,323 Reduced 2.23%	540,125 $0
Q2 2018 Sep 19, 2018	BUY	$64.88 - $75.68 $35.8 Million - $41.8 Million	552,448 New	552,448 $39.1 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Royal London Asset Management LTD with notifications on news.

Account

Royal London Asset Management LTD Gilead Sciences, Inc. Transaction History